SP1 and ovarian carcinoma: In this study, we observed that 6RK73, as a potential anti-cancer agent, significantly inhibited ovarian cancer cell growth and cell cycle progression by attenuating AKT1/ Sp1/c-Myc signaling, independent of UCHL1 inactivation.